Therefore, all these results support the potential role of CEA and LDH levels as predictive tumor biomarkers in CRC patients. Moreover, the combined assessment of these tumor biomarkers, with possibly other parameters, rather than relying on a single element, can facilitate the early detection of CRC recurrence, besides their utilization as a prognostic tool and eventually during the follow-up of anticancer therapy. The gene discussed is CEACAM5; the disease is colorectal carcinoma.